CO5160294A1 - Composicion farmaceutica que inhibe o detiene el crecimiento de virus en animales particularmente mamiferos sarrollo de virus en animales y composiciones farmaceuticas que los contienen - Google Patents

Composicion farmaceutica que inhibe o detiene el crecimiento de virus en animales particularmente mamiferos sarrollo de virus en animales y composiciones farmaceuticas que los contienen

Info

Publication number
CO5160294A1
CO5160294A1 CO00023489A CO00023489A CO5160294A1 CO 5160294 A1 CO5160294 A1 CO 5160294A1 CO 00023489 A CO00023489 A CO 00023489A CO 00023489 A CO00023489 A CO 00023489A CO 5160294 A1 CO5160294 A1 CO 5160294A1
Authority
CO
Colombia
Prior art keywords
animals
viruses
inhibites
viruss
stops
Prior art date
Application number
CO00023489A
Other languages
English (en)
Inventor
Camden James Berger
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of CO5160294A1 publication Critical patent/CO5160294A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención revela un derivado de (5-aril-1,2,4-tiadiazol)-3-ilo-tiourea ó derivado de (5-aril-1,2,4-tiadiazol )-3-ilo urea de la fórmula:<EMI FILE="00023489_1" ID="1" IMF=JPEG >donde X es oxígeno o azufre, R es hidrógeno o alquilo que tiene desde 1 hasta 7 átomos de carbono, cloro, bromo o flúor, oxicloro, alcoxi que tiene la fórmula -O(CH2) y CH3 donde y es de desde 1 hasta 6 ó una sal de adición farmacéuticamente aceptable prodroga de ella.Igualmente, revela una composición farmacéuticamente que inhibe o retarda el desarrollo de virus en animales, particularmente mamíferos. La misma composición puede ser usada para tratar infecciones virales, particularmente hepatitis C, herpes simple, sarcoma de Kaposi y VIH. La composición preferiblemente contiene desde 10 mg hasta 6.000 mg.
CO00023489A 1999-03-31 2000-03-31 Composicion farmaceutica que inhibe o detiene el crecimiento de virus en animales particularmente mamiferos sarrollo de virus en animales y composiciones farmaceuticas que los contienen CO5160294A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28189699A 1999-03-31 1999-03-31

Publications (1)

Publication Number Publication Date
CO5160294A1 true CO5160294A1 (es) 2002-05-30

Family

ID=23079226

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00023489A CO5160294A1 (es) 1999-03-31 2000-03-31 Composicion farmaceutica que inhibe o detiene el crecimiento de virus en animales particularmente mamiferos sarrollo de virus en animales y composiciones farmaceuticas que los contienen

Country Status (11)

Country Link
US (2) US6258831B1 (es)
EP (1) EP1165070B1 (es)
JP (1) JP2002540156A (es)
AR (1) AR019505A1 (es)
AT (1) ATE297729T1 (es)
AU (1) AU763573B2 (es)
CA (1) CA2368615C (es)
CO (1) CO5160294A1 (es)
DE (1) DE60020820T2 (es)
PE (1) PE20001644A1 (es)
WO (1) WO2000057878A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423695B1 (en) * 1998-01-13 2002-07-23 Ribapharm, Inc. Cytokine related treatments of disease
US6245788B1 (en) * 1999-03-31 2001-06-12 The Procter & Gamble Company Viral treatment
DE10120627A1 (de) 2001-04-26 2002-10-31 Cmi Ag Verwendung von Phyllanthusbestandteilen zur Behandlung oder Prophylaxe von Infekten durch Hepatitis B-Viren
US20050239054A1 (en) * 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
PL211979B1 (pl) 2002-04-26 2012-07-31 Gilead Sciences Pochodne fosfonianowe, ich zastosowanie w leczeniu zakażenia wirusem HIV i chorób wpływających na białe krwinki, oraz kompozycje farmaceutyczne zawierające te związki
US20040010036A1 (en) * 2002-05-07 2004-01-15 Boris Rogovoy N,N, -Substituted s-Aryl-Isothioureas, N,N,N, -Substituted s-Aryl-Isothioureas and combinatorial libraries thereof
JP4733393B2 (ja) * 2002-11-18 2011-07-27 ポラリス・グループ インビボでウイルス複製を阻害する方法
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
US7300924B2 (en) * 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
WO2005002626A2 (en) * 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
CN101410120A (zh) * 2003-04-25 2009-04-15 吉里德科学公司 抗炎的膦酸酯化合物
WO2004096286A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Antiviral phosphonate analogs
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7432261B2 (en) * 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
MXPA05011296A (es) 2003-04-25 2006-01-24 Gilead Sciences Inc Conjugados de fosfonato inhibidores de la cinasa.
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
EP1678321A1 (en) 2003-10-24 2006-07-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
US7427624B2 (en) 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
US7253175B2 (en) * 2003-11-13 2007-08-07 Barnet Liberman Method for treating athlete's foot
US8592368B2 (en) 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
US20050153990A1 (en) * 2003-12-22 2005-07-14 Watkins William J. Phosphonate substituted kinase inhibitors
US7432272B2 (en) * 2003-12-22 2008-10-07 Gilead Sciences, Inc. Antiviral analogs
BRPI0418031A (pt) * 2003-12-22 2007-04-17 Gilead Sciences Inc inibidores de quinase fosfonato-substituìdos
TW200600492A (en) * 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
WO2006110157A2 (en) 2004-07-27 2006-10-19 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
US20060264422A1 (en) * 2005-05-09 2006-11-23 Johannes Reinmueller Use of taurolidine as enhancer of the complement system
JP2009510122A (ja) * 2005-09-29 2009-03-12 ザ スクリプス リサーチ インスティテュート ウイルスペプチドおよびフラビウイルス科のウイルスに対してウイルス感染を阻害するためのその使用
US7480400B2 (en) * 2006-03-16 2009-01-20 Siemens Medical Solutions Usa, Inc. Detection of fiber pathways
PL2307435T3 (pl) 2008-07-08 2012-11-30 Gilead Sciences Inc Sole związków inhibitorów HIV
PL3661937T3 (pl) 2017-08-01 2021-12-20 Gilead Sciences, Inc. Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych
AU2019324089B2 (en) 2018-08-21 2024-06-13 Kyorin Pharmaceutical Co., Ltd. Bicyclic heteroaromatic ring derivative
CN112245570A (zh) * 2019-07-22 2021-01-22 厦门特宝生物工程股份有限公司 一种基于干扰素的疾病治疗方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353920A (en) * 1980-08-25 1982-10-12 Olin Corporation Use of selected 3-trihalomethyl-5-ureido-1,2,4-oxadiazoles and -1,2,4-thiadiazoles as agricultural viricides
JPS57136579A (en) * 1981-01-21 1982-08-23 Mitsui Toatsu Chem Inc Thiazolylurea derivative, its preparation, and pharmaceutical composition containing the same
US4835168A (en) * 1985-12-16 1989-05-30 Eli Lilly And Company Thiadiazole antiviral agents
US5256680A (en) * 1988-11-29 1993-10-26 Warner-Lambert Company 3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents
US5593993A (en) 1991-08-02 1997-01-14 Medivir Ab Method for inhibition of HIV related viruses
IL102548A (en) 1991-08-02 1998-08-16 Medivir Ab Use of painting derivatives in the preparation of drugs for VIH inhibition and treatment of SDIA and new compounds
JPH07149748A (ja) * 1993-09-30 1995-06-13 Souyaku Gijutsu Kenkyusho:Kk チアジアゾール誘導体及びその製造法
JPH08169881A (ja) * 1994-09-22 1996-07-02 Soyaku Gijutsu Kenkyusho:Kk アリールチアジアゾール誘導体及びそれを含有する抗ウイルス剤
JPH08245384A (ja) * 1995-03-13 1996-09-24 Soyaku Gijutsu Kenkyusho:Kk 抗ウイルス剤
US6162791A (en) 1998-03-02 2000-12-19 Apotex Inc. Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes

Also Published As

Publication number Publication date
EP1165070A1 (en) 2002-01-02
US20010031773A1 (en) 2001-10-18
ATE297729T1 (de) 2005-07-15
DE60020820T2 (de) 2006-05-04
AU763573B2 (en) 2003-07-24
AU4182200A (en) 2000-10-16
JP2002540156A (ja) 2002-11-26
DE60020820D1 (de) 2005-07-21
WO2000057878A1 (en) 2000-10-05
AR019505A1 (es) 2002-02-20
PE20001644A1 (es) 2001-02-06
CA2368615C (en) 2007-01-02
US6258831B1 (en) 2001-07-10
EP1165070B1 (en) 2005-06-15
US6410575B2 (en) 2002-06-25
CA2368615A1 (en) 2000-10-05

Similar Documents

Publication Publication Date Title
CO5160294A1 (es) Composicion farmaceutica que inhibe o detiene el crecimiento de virus en animales particularmente mamiferos sarrollo de virus en animales y composiciones farmaceuticas que los contienen
AR019305A1 (es) Hiv y tratamiento viral.
KR890016046A (ko) 2-치환-4-치환-1,3-디옥솔란, 이의 합성 및 이의 용도
CO5150150A1 (es) 4-oxo-1,4-dihidro-3-quinoleincarboxamidas como agentes antivirales
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
EA200300023A1 (ru) 3&#39;-ПРОЛЕКАРСТВА 2&#39;-ДЕЗОКСИ-β-L-НУКЛЕОЗИДОВ
ATE242634T1 (de) Benzimidazolderivaten-enthaltende pharmazeutische zusammensetzungen zur inhibierung des krebswachstums
CO5280097A1 (es) Aminoacidos ciclicos y sus derivados utiles como agentes farmaceuticos
CO5160292A1 (es) Composicion farmaceutica que contiene derivados de 2-tienil- imidazolo[4,5]piridina, util para el tratamiento de infeccio nes virales
PE20010541A1 (es) Uso de una composicion de benzimidazol para tratar el cancer
CO5200760A1 (es) Antagonistas del receptor de la il-8 ceptor il-8
KR910004591A (ko) 헤테로 고리 화합물
CO5080762A1 (es) Antagonistas de receptor de vitronectina
AR037940A1 (es) Compuestos antivirales de piridoquinoxalina
CO5150179A1 (es) Derivados de n-etilpirimidin o (piridin)-2-(1,2-benzoisoxa- zol-3-il)-octahidro-2h-pirido[1,2-a]pirazina y sus composiciones farmaceuticas
CO5140099A1 (es) Ciertas caprolactamas sustituidas, composiciones farmaceuticas que las contienen, y su uso en el tratamiento de tumores
ATE320480T1 (de) Von der seebarsch epinephelus coioides derivierte unsterbliche zellinie und ihre verwendungen
CO5160293A1 (es) Composicion farmaceutica que inhibe o detiene la infeccion o reinfeccion de animales, particularmente mamiferos, por vih u otros retroviruses
CO5080752A1 (es) INHIBIDORES DEL FACTOR DE TRANSCRIPCION NF-kB
CO5251424A1 (es) Oxazinquinolonas utiles en el tratamiento de infecciones virales
ES2105923B1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
KR900018093A (ko) 2&#39;,3&#39;-디데히드로-2&#39;,3&#39;-디데옥시뉴클레오사이드류의 전구체
KR940005612A (ko) 벤조디아제핀
WO2002041891A3 (en) Hiv treatment with benzimidazoles
KR910021407A (ko) 바이러스에 의해 유발된 질환을 치료하기 위한 벤질포스폰산 유도체의 용도